2038738
Last Update Posted: 2014-01-17
Recruiting status is unknown
All Genders accepted | 18 Years + |
250 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.
Eligibility
Relevant conditions:
Neuroendocrine
Neuroendocrine Tumor
Neuroendocrine Cancer
Neuroendocrine Carcinoma
Carcinoid
Carcinoid Tumor
Islet Cell Tumor
Apudoma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Richard J. Campeau, M.D.
504-464-8500
Data sourced from ClinicalTrials.gov